Stockscreener 앱 받기
25.47
1.36%
-0.35
시장 영업 전:
26.00
0.53
+2.08%
Alto Neuroscience Inc 주식(ANRO)의 최신 뉴스
Wall Street Recap: Is Alto Neuroscience Inc benefiting from interest rate changes2026 Earnings Surprises & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Alto Neuroscience (ANRO) price target increased by 15.20% to 36.72 - MSN
Alto NeuroscienceProposed resale of up to 6 million shares of common stock by selling stockholdersSEC filing - marketscreener.com
Alto Neuroscience (NYSE: ANRO) registers 6M resale shares from private placement - Stock Titan
Top 1% Alto Neuroscience plummets on its shocking schizophrenia miss - MSN
What Do Analysts Think About the Biopharma Set on Transforming Psychiatry - Streetwise Reports
California Biotech Co. Advances Depression Drug Breakthrough - Streetwise Reports
Analysts Conflicted on These Healthcare Names: Merck & Company (MRK) and Alto Neuroscience, Inc. (ANRO) - The Globe and Mail
H.C. Wainwright reiterates Alto Neuroscience stock rating at buy By Investing.com - Investing.com Canada
ANRO stock on investors’ radar after failed schizophrenia study results - MSN
Alto Neuroscience, Immunovant and other big stocks moving lower in Thursday's pre-market session - MSN
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Alto Neuroscience, Inc. (ANRO) - The Globe and Mail
Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results - Sahm
Why Globalstar Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Sahm
Chardan Capital Remains a Buy on Alto Neuroscience, Inc. (ANRO) - The Globe and Mail
Alto Neuroscience Price Target Cut to $21.00/Share From $22.00 by Wedbush - Moomoo
Alto Neuroscience Shares Fall After Phase 2 Trial of ALTO-101 Yields Statistically Insignificant Data - marketscreener.com
Alto Neuroscience (ANRO) Receives Reiterated "Buy" Rating by HC Wainwright & Co. | ANRO Stock News - GuruFocus
Alto Neuroscience (NYSE:ANRO) Given New $38.00 Price Target at Robert W. Baird - MarketBeat
HC Wainwright Reaffirms Buy Rating for Alto Neuroscience (NYSE:ANRO) - MarketBeat
JonesTrading Issues Pessimistic Forecast for Alto Neuroscience (NYSE:ANRO) Stock Price - MarketBeat
Alto Neuroscience (NYSE:ANRO) Shares Gap Down After Analyst Downgrade - MarketBeat
Wedbush Lowers Alto Neuroscience (NYSE:ANRO) Price Target to $21.00 - MarketBeat
Jefferies Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Raises Target Price to $35 - Moomoo
JonesTrading Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Cuts Target Price to $44 - Moomoo
A Quick Look at Today's Ratings for Alto Neuroscience(ANRO.US), With a Forecast Between $30 to $44 - Moomoo
Alto Neuroscience (NYSE:ANRO) Earns Buy Rating from Chardan Capital - MarketBeat
Wedbush Cuts Price Target on Alto Neuroscience to $21 From $22, Keeps Neutral Rating - marketscreener.com
Alto Neuroscience Announces Phase 2 Results for ALTO-101, Prioritizes ALTO-207 in Treatment-Resistant Depression Pipeline 123 - Minichart
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Conc - The National Law Review
Alto Neuroscience stock falls after trial misses primary endpoint By Investing.com - Investing.com Canada
Chardan Capital Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Alto Neuroscience’s ALTO-101 misses primary endpoint in trial By Investing.com - Investing.com South Africa
Stocks to Watch: Franklin Covey, Penguin Solutions, Alto Neuroscience - Moomoo
ANRO Stock Falls After Hours On Failed Schizophrenia Study Results - Stocktwits
Alto Shifts Focus to ALTO-207 After ALTO-101 Data - TipRanks
After the highly anticipated study on cognitive function in schizophrenia failed to meet its primary clinical endpoint, biopharmaceutical company Alto Neuroscience Inc (ANRO) suffered a sharp decline in after-hours trading, plunging by 18.8% and closing at $19 - Bitget
Alto Neuroscience reports topline data from phase 2 proof-of-concept study of Alto-101 and highlights pipeline advancements - marketscreener.com
Alto Neuroscience’s ALTO-101 misses primary endpoint in trial - Investing.com
Alto Neuroscience Inc announced the successful development of an improved once-daily extended-release oral formulation of Alto-101. - Bitget
Alto Neuroscience's Phase 2 Trial of ALTO-101 Yields Statistically Insignificant Data - marketscreener.com
Alto Neuros Reports Topline Phase 2 Data for ALTO-101; ALTO-207 Phase 2b on Track, $275M Cash - TradingView — Track All Markets
Alto Neuroscience (NYSE: ANRO) shifts focus to ALTO-207 after ALTO-101 miss - Stock Titan
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements - Eagle-Tribune
Alto Neuroscience (NYSE:ANRO) Trading 9.1% HigherHere's Why - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
2.69%
0.25%
자본화:
|
볼륨(24시간):